The development of xenogeneic anticancer vaccines (XAV) started at the end of the 1990s, when it was shown that the use of xenogeneic analogues of tumor associated antigens enables the body to overcome immunological toleration for its own proteins [1] . Now, it is proven that a number of tumor associated antigens and protein have their counterparts of animal or avian origin which can serve as antigens in XAV. These proteins or genes are exploited in the construction of XAVs, some of which have been shown to have anticancer effect [2, 3] . Some XAV successfully passed I-II phases of clinical trials. Their safety and ability to induce immune response without autoimmune complications have been proven [4] [5] [6] [7] [8] . Among others, genes and proteins of chicken origin which share homology with human counterparts are exploited in the XAV construction [9] [10] [11] [12] [13] [14] .
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At the R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology (IEPOR) of the National Academy of Science of Ukraine XAV based on chicken embryo proteins (CEP) is under deve lopment. It is known that anticancer vaccines based on one or several antigens can lead to an immune edi ting of the tumor so that it loses antigens targeted by the vaccine. Moreover, polyantigenic vaccines potentially can elicit an immune response to a wider range of cancer antigens including unidentified ones [15] . That is why the vaccine which is being constructed is designed to be polyantigenic and is based on proteins extracted from the chicken embryo. In preliminary experiments, it was shown that blood serum of mice bearing different tumor strains has antibodies which react with CEP [16] . When injected to intact mice CEP caused no side effect or allergy reactions [17] . The aim of the current work is to evaluate the anticancer activity of CEP-based vaccine administered by different vaccination schedules.
MATERIALS AND METHODS
The study has been carried out on male C57Bl/6 mice 2-2.5 months old weighing 19-20 g, bred in the IEPOR. The use and care of the experimental animals have been performed in accordance with the standard international rules of biologic ethics and was approved by Institutional Animal Care and Use Committee [18, 19] . The anticancer and antimetastatic efficacy of CEP was examined when vaccination was applied prior to tumor cells injection (prophylactic schedule), after tumor transplantation (therapeutic vaccination) or after tumor removal (post surgery vaccination). Lewis lung carcinoma (LLC) was used as the model of tumor growth.
CEP was prepared as follows [20] : 7 days chicken embryos were rinsed two times briefly in cold 0.9% NaCl solution, homogenized and then extracted with 0.9% NaCl solution containing 0.1% EDTA, for 60 min at 4 °C by agitation. Following the extraction, chicken embryo tissue was removed by centrifugation at 1.500 g for 30 min. The resulting supernatant was collected and frozen at −20 °C. Tumor associated antigens of LLC (LLC-Ag) were prepared by three consecutive cycles of freezing and melting of cell suspension. Following the last melting, cell debris was removed by centrifugation at 1.500 g for 30 min. The resulting supernatants were collected and frozen at −20 °C. The concentration of proteins in the extracts was measured by Greenberg and Craddock assay [21] . The same extracts were used in all the experiments described in the article.
Irrespective of vaccination schedule, CEP or LLCAg immunizations were performed s.c. with 0.3 ml solution per mouse (protein concentration 0.3 mg/ml).
According to the prophylactic experiment, mice were immunized with CEP or LLC-Ag (three weekly injections); LLC cells were transplanted 30 To assess metastasis burden mice were sacrificed and in each animal lungs were removed; surface lung metastases were counted and measured. The metastases volume was calculated as following:
/3, where r -stands for the metastases radius. The percentage of mice bearing metastases is referred as metastases rate. The mean number of metastases was calculated per all the mice in group and per mice bearing metastases.
Metastasis Inhibition Index (MII) was calculated as following:
, where А c and А i stand for the number of mice bearing lung metastases in groups of control and immunized mice respectively. В c and В i stand for the mean number of lung metastases in groups of control and immunized mice respectively [22] . The results were analyzed for statistical significance by paired t-test using StatSoft STATISTICA 7.0. Values p < 0.05 were considered as statistically significant [23, 24] . The data in figures and tables are presented as M ± SD.
RESULTS
The anticancer activity of CEP applied before tumor transplantation (prophylactic immunization). CEP or LLC-Ag were injected three times with one-week intervals. Then 30 days after the last immunization, LLC was transplanted into both unvaccinated animals (the control) and mice vaccinated with CEP or LLC-Ag. LLC tumor appeared in 81.0% (17 out of 21) of the control mice (Table 1 ). In the treatment groups, 77.8% (7 out of 9) and 81.8% (9 out of 11) of mice immunized with LLC-Ag or CEP, respectively, developed LLC tumors. The difference between all the groups was not significant. The latent period of tumor development was shorter (p < 0.05) in the group of the control mice (7.8 days) compared to the mice pre-vaccinated with LLC-Ag (10.0 days) or CEP (10.9 days). The tumor growth kinetics is shown in Fig. 1 . During the experiment, the smallest tumor volume was observed in the group of mice immunized with CEP (p < 0.05 compared to the control group). In the group of CEP-immunized mice, the ITGI reached 35.8-48.8% depending on time after the tumor transplantation. The tumor volume of mice immunized with LLC-Ag did not differ significantly compared to both control and CEPimmunized mice. In the group of LLC-Ag-immunized mice, the maximal ITGI (28.4%) was observed on the 14 th day after the tumor transplantation (Table 2) .
On day 28 after LLC transplantation, all the mice of the control and treatment groups were euthanized so the metastases rate to be evaluated. The results are shown in Table 3 .
In the mice vaccinated with CEP, 73.4% reduction of the mean metastasis volume was registered, in particular, 51.5 and 72.1% decrease of the metastases number per mouse or per mouse in the group correspondingly. So, in this group MII reached 59.5% per metastases-bearing mouse and 71.1% per group. Contrary to CEP, LLC-Ag vaccination was not effective against metastases development. The anticancer activity of the CEP-based vaccination applied after the tumor transplantation (therapeutic vaccination). Therapeutic vaccination with CEP has been performed according to three different schedules of vaccination (described in details in the Materials and Methods section). Any of immunization schedules appeared to be superior in transplantation efficacy and latent period of LLC development, as far as 85.9-89.6% of the vaccinated and control mice developed tumors on the 9-11 th day after the LLC cells transplantation.
When it comes to the tumor volume, the most evident effect on tumor growth was observed in the group of mice vaccinated according to the schedule #1 (Fig. 2) . Compared to the control group, the difference was significant (p < 0.05) till the 20 th day after the tumor challenge. The ITGI reached 53.13% on 14 th day after the LLC transplantation and was decreasing slowly till the 28 th day of the experiment. Although the ITGI (42.1%) observed at this time point of the follow-up period (the 28 th day after the LLC transplantation) was the lowest for the group #1, it remained to be the highest among the other groups. The tumor volume of the mice vaccinated according to the two other schedules did not differ significantly compared with the control group.
On day 28 after the tumor transplantation, all the mice were euthanized to assess the metastasis loading (Table. 4 ). The results of the group #1 were out-standing. In this group, the lowest mean metastases number per group was recorded (0.05 < p < 0.1 compared to the control group). The mean metastases volume was by 54.4% lower than that in the control group. So, the MII in group #1 reached 77.6% (per group) or 66.3% (per mice bearing metastases) and was the highest among all the treatment and control groups. In other treatment groups, the results did not differ significantly from that of the control group. It is worth mentioning that only in the group #1 all the mice were still alive till the end of the experiment (28 days after tumor transplantation). The worst survival rate was in the group #3 (here the vaccination started after the tumor nodule could be palpable), in which 50% of immunized mice died before the experiment termination. The anticancer activity of CEP applied after the tumor resection (post surgical therapeutic vaccination). As far as the most prominent anticancer results were observed in the group of mice immunized on the 1 st , 7 th and 14 th days after tumor transplantation (group #1), the same schedule was chosen to be applied in the study of post surgical therapeutic vaccination. Mice were transplantated with LLC cells (per foot); on the 17 th day after transplantation the tumor nodule was removed. All the mice were divided into two groups. The mice in the CEP group underwent vaccinations with CEP on the 1 st , 7 th and 14 th days after tumor resection. On the 35 th and 50 th days after the tumor transplantation (the 18 th and 34 th days after the tumor removal, respectively) the mice of both (control and treatment) groups were euthanized to assess the metastases burden (Table 5 ). In this experimental setting, CEP showed evident and long-lasting antimetastatic effect. Independently on observation time, CEP immunization led to reduction of the metastases rate, metastases number and volume. For example, on the 18 th day after the tumor removal, only 27.3% of the immunized mice had metastases, while in the control group this index reached 72.7% (the difference was statistically significant). The metastases volume in the group of vaccinated mice was by 98.3% lower (p < 0.05) when compared to the control mice. The mean number of metastases per metastases-bearing mouse or per group in total was statistically significantly lower in the group of CEP vaccinated mice. So, MII reached 91.7% per mouse and 96.9% per group.
On the day 34 th after the tumor removal, mice in the control group showed disease progression. For example, the metastases volume increased by 1.92 times, compared with the 18 th day after the tumor removal. The mean number of metastases slightly decreased possibly due to the merging of small metastases. The metastasis rate did not change significantly (66.7 ± 13.6 and 72.7 ± 13.4% of control mice had metastases on the 34 th and 18 th days after the tumor removal respectively).
On the other hand, mice immunized with CEP showed stabilization of metastatic process. In particular, the metastases volume was 0.8 ± 0.4 mm 3 (to compare, it was 1.2 ± 0.9 mm 3 on the 18 th day after the tumor removal); the metastases number per mouse bearing it was 1.5 ± 0.7 (3.7 ± 1.1 on the day 18 th of examination). In control mice, metastasis rate in the group of vaccinated mice did not differ significantly from the previous point of observation.
So, we can assume that on the 18 th day after the tumor removal almost all the mice (of both control and treatment groups) which were prone to develop metastases developed them, as long as the metastasis rate did not differ significantly on the 18 th and 34 th days of observation. But the metastasis rate was statistically lower in the CEP vaccinated group during all the experiment (i.e. on the 18 th and 34 th days after tumor removal) compared to the control. What is important, the vaccinated mice showed inhibition of metastases growth, whereas in the control group the mean metastases volume increased by almost 2 times. As a result, the mean metastases volume in the group of immunized mice was by 94.4% lower than that in the control group. In the CEP group, the MII calculated per group was equivalent to 97.8%. So, the antimetastatic effect of CEP-based vaccination was observed for a prolonged period of time even after the termination of the vaccination.
DISCUSSION
So, as it was shown in the model of LLC, vaccination with CEP appears to have anticancer and antimetastatic effects. In the previous experiments it has been shown that there were CEP-specific antibodies in the blood serum of mice bearing different tumor strains (LLC, sarcoma 37, Ehrlich carcinoma, melanoma B-16) [16] . The presence of CEP-specific antibodies in the blood serum of unimmunized tumor-bearing mice may be explained by at least two reasons: polyspecific antibody circulation [25, 26] and the pre sence of some homologous proteins in CEP. It is known that some proteins of chicken origin share homology with mammals proteins, including that of human and mice [9, 10, 12, [27] [28] [29] . The anticancer effect of CEP seems to be based on the last assumption. Especially, it looks possible when we consider the antitumor and antimetastatic effects of CEP applied before the tumor challenge -in so called prophylactic settings. According to the prophylactic schedule which was applied in the experiment, the tumor cell injection was performed on the 30 th day after the last immunization. Till the 30 th day after the CEP injection, the immune response induced by the immunization was expected to terminate [30] , but immune memory cells had been already established [31] . The immune memory is capable of mounting a rapid response to subsequent antigen stimulation [32] . In the experiment, LLC cell suspension in the dose sufficient to induce tumors was used instead of the antigen re-challenge. Since a statistically significant prolongation of the latent period of tumor development in the groups of immunized mice was observed, it points to the generation of the rapid immune response to the cancer cells injection. That is, the mice immunized with CEP or LLC-Ag in the prophylactic mode mounted a rapid immune response to cancer cells as if it was an antigen re-challenge.
Subsequently, the observed results indicate with high probability that CEP contains some proteins which share homology with LLC antigens and immunization with CEP leads to immune memory formation. Moreover, in terms of its antimetastatic activity, vaccination with CEP was much more effective than application of LLC-Ag. This finding can be considered as an additional demonstration that xenogeneic homologous proteins are useful for breaking immune tolerance towards autologous cancer antigens.
In case of therapeutic immunization, the anticancer effect of CEP was evident only when applied at the very early stage of tumor formation (24 h after tumor cells injection, group #1), when tumor burden is minimal. When vaccination was postponed to only 7 days (group #2) the anticancer effect could hardly be observed. Furthermore, vaccination with CEP has no anticancer effect when applied to mice with the already established tumor (group #3). So, it can be concluded that without prior tumor removal the application of anticancer vaccine based on CEP will have a minimal anticancer effect in clinical settings. On the other hand, it confirms a generally acknowledged statement that benefit of an anticancer vaccine is most evident when it is applied in earlier and less aggressive disease settings, that is in settings of minimal residual disease [33, 34] .
Owning to this, the third experiment -application of CEP after the surgical resection of the tumorwas conducted. In this case, CEP application had a pronounced and long-lasting antimetastatic effect. The number of metastases bearing mice and the mean metastases volume were significantly reduced in the group of treated mice. These effects were evident till the 34 th day after the tumor removal -the day of the experiment termination. It should be mentioned that the mean metastases volume in the CEP group was 60 and 168.5 times smaller than that of the control group on the 18 th and 34 th days after the tumor resection respectively. MII was very high and reached 96.9 and 97.8% per group in total on the 18 th and 34 th day respectively. It can be assumed that this vaccine when applied after the surgical removal of a tumor may dramatically improve therapeutic efficacy of cancer treatment, as long as metastatic spread of a tumor is the main death cause of cancer patients [35] . It has been shown that some genes or proteins of chicken origin, when used as a xenogeneic vaccine, can elicit anticancer effect or tumor specific immune response. For example, xenogeneic vaccines based on chicken HSP70 [11], MMP-2 [10, 14] , Tie-2 [9] or FGFR [12, 13] were effective in case of LLC [10, 14] , fibrosarcoma Meth A [13, 10] , hepatoma H22 [9, 10] , melanoma B-16 [9] , CT26 colon adenocarcinoma [14] , canine cancer [11] . Anticancer effects of CEP are comparable with these of the vaccines mentioned above. Whether CEP contains some of abovementioned proteins or its anticancer effect is based on other antigens it remains to be elucidated.
CONCLUSION
Vaccination based on CEP exhibited both prophylactic and therapeutic anticancer effects. The last one is more pronounced when the vaccination starts shortly after the primary tumor resection. In this case, the MII reaches 91.7%. So, CEP are suitable to be used in xenogeneic cancer vaccine construction.
